News

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera ...
MedPage Today on MSN6d
BTK Inhibitors for Multiple Sclerosis
Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...
Nature5d
G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors
The N-methyl-D-aspartate (NMDA) receptor contributes to synaptic plasticity in the central nervous system and is both serine-threonine and tyrosine phosphorylated. In CA1 pyramidal neurons of the ...
HER2-low Cancers Market Set to Register Immense Growth at a CAGR of 9.4% During the Study Period (2020-2034) | DelveInsight
Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...
Pulmonology Advisor4d
Patritumab Deruxtecan BLA Withdrawn After Missing Overall Survival Endpoint
Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.
The Manila Times5d
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...
Clinical Trials Arena on MSN2d
Enrolment concludes in Phase III trial of Dizal’s sunvozertinib for NSCLC
Dizal has completed subject enrolment for the randomised Phase III WU-KONG28 trial of oral sunvozertinib for treating NSCLC ...
Targeted Oncology6d
Cellular Therapies Show Safety in B-Cell Malignancies
The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data ...